2010 Multidisciplinary Head and Neck Cancer Symposium
Click here to go to the previous page
Program Code:
03
Date:
Thursday, February 25, 2010
MODERATOR(S):
Click the plus sign to see more detailed information
about each speaker.
I am Chief, Head and Neck Oncology at Fox Chase Cancer Center; Chair, Head and Neck Committee in ECOG; Member of the NCI Head and Neck Cancer Steering Committee; Member of the NCCN Head and Neck Cancer Guidelines Committee; have authored many original articles and reviews on the topics of head and neck cancer biology, use of cetuximab, and role of HPV infection in head and neck cancer.
|
Barbara Murphy,
M.D., Assistant Professor,
Vanderbilt-Ingram Cancer Center
Director, Pain and Symptom Management Program for the Vanderbilt Ingram Cancer Center
Leader, Head and Neck Research Team for the Vanderbilt Ingram Cancer Center
Area of research: head and neck cancer symptom control including: swallowing and nutritional outcomes, neuopsychologic effect of therapy, lymphedema, and oral health outcomes
|
Michael Kupferman, M.D., M.D. Anderson Cancer Center
David Raben,
M.D., Radiation Oncologist,
University of Colorado Comprehensive Cancer Center
Dr. David Raben is a board certified radiation oncologist at the University of Colorado. Residency training in radiation oncology was conducted at the John Hopkins Hospital (1991-1994). Presently, he is a full professor and scientist in the only NCI-designated Comprehensive Cancer Center in the Rocky Mountain region at the University of Colorado Denver. Dr. Raben is nationally recognized regarding his work in targeted therapies and radiation, primarily in GI, head and neck cancer and lung cancer. He serves on the head and neck steering committee of the National Cancer Institute sponsored radiation cooperative group (RTOG). In addition, he is a member of the GU section of the SWOG and has extensive experience with both low dose (LDR) and high dose rate (HDR) brachytherapy. The UCD Radiation Oncology Dept. was the only site approved by the RTOG in Colorado to participate in the national phase II HDR brachytherapy trial. In addition, Dr Raben was the first radiation oncologist in the Rocky Mountain region to implement accelerated intensity modulated radiation to the prostate and pelvis, recently published in a peer-reviewed journal. His focus has also been on blocking critical growth, invasion and angiogenic signaling pathways driving cancer cells to enhance radiation therapy. He is an ad hoc reviewer for Cancer Research, Clinical Cancer Research, Head and Neck, Journal of Clinical Oncology and the International Journal of Radiation Oncology, Biology and Physics. He serves as the Director of the Radiological Sciences Core at the Cancer Center. Dr. Raben has contributed to 77 publications.
|
SPEAKER(S):
Gilles Calais
Nicola Caria
Marco Cianchetti
Jeremy Setton
Bharat Mittal
Claris Smith
Navesh Sharma, D.O., Ph.D., Fox Chase Cancer Center, Philadelphia, PA
David Sher, M.D., M.P.H., Dana-Farber Cancer Institute
Gregory Chronowski